Title
Impact of rapid drug susceptibility testing for tuberculosis: Program experience in Lima, Peru
Date Issued
01 November 2012
Access level
open access
Resource Type
journal article
Author(s)
Shin S.
Yale G.
Contreras C.
Atwood S.
Blaya J.
Ershova J.
Cegielski J.
Abstract
SETTING: Programmatic implementation of decentralized rapid drug susceptibility testing (DST) in Lima, Peru. OBJECTIVE: Pre-post analysis compared time to diagnosis, treatment outcome and survival among patients tested with direct nitrate reductase assay (NRA) vs. indirect conventional methods. DESIGN: From 2005 to 2009, we prospectively followed all patients referred for DST before (control) and after (intervention) NRA implementation. Among those referred for DST, NRA was used for smear-positive samples of patients with no prior history of multidrug resistance or treatment for multidrug-resistant tuberculosis (TB). Data were abstracted from patient charts and laboratory registers. Endpoints were favorable outcomes, time to result and time to death. RESULTS: Of those patients who met the criteria for NRA, 740 underwent NRA and 621 underwent conventional DST. NRA yielded test results for 78.4% of cases vs. 68.8% for conventional DST (P < 0.0001); the median time to result was 44 vs. 133 days, respectively (adjusted HR 0.64, 95%CI 0.56-0.73). Among individuals without previous anti-tuberculosis treatment, NRA was associated with a favorable treatment outcome (adjusted OR 1.39, 95%CI 1.01-1.90) and prolonged survival (adjusted HR 0.53, 95%CI 0.31-0.90). CONCLUSION: Direct NRA significantly shortened time to test result and improved treatment outcomes and survival in certain groups. © 2012 The Union.
Start page
1538
End page
1543
Volume
16
Issue
11
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Tecnología para la identificación y funcionamiento del ADN, proteínas y enzimas y como influencian la enfermedad)
Subjects
Scopus EID
2-s2.0-84867216521
PubMed ID
Source
International Journal of Tuberculosis and Lung Disease
ISSN of the container
10273719
Sponsor(s)
National Institute of Allergy and Infectious Diseases K23AI054591 NIAID
Sources of information:
Directorio de Producción Científica
Scopus